Chronic Insomnia: 5 Critical Clinical Insights
An evidence synthesis of CBT-I as first-line therapy, dual orexin receptor antagonists, hypnotic safety, and deprescribing frameworks for chronic insomnia in family medicine practice.
One-Minute Takeaway on Chronic Insomnia
One-Minute Takeaway
- Chronic insomnia is most effectively treated with multicomponent cognitive behavioral therapy for insomnia (CBT-I), endorsed as first-line by the AASM (strong recommendation, 2021) and ACP (strong recommendation, 2016) based on consistent randomized evidence.
- Pharmacotherapy carries weak or conditional recommendations only and is reserved for patients who decline, lack access to, or fail an adequate CBT-I trial.
- Dual orexin receptor antagonists (suvorexant, lemborexant, daridorexant) provide a generally favorable safety profile relative to benzodiazepine receptor agonists, but increase next-day somnolence rates compared with placebo.
- Benzodiazepines and Z-drugs carry meaningful risks (falls, fractures, dependence, complex sleep behaviors) — particularly in adults aged 65 and older, where Beers Criteria recommend avoidance.
- Structured deprescribing using direct patient education achieves up to 27% benzodiazepine discontinuation at 6 months, supporting active rather than passive review of long-term hypnotic use.
Why Chronic Insomnia Demands a Stepped-Care Approach
Chronic insomnia disorder affects approximately 10% of adults and is one of the most frequent presenting complaints in primary care. It is associated with reduced quality of life, increased healthcare utilization, and elevated risks of cardiovascular disease, depression, and motor vehicle collisions.
Despite multiple guidelines positioning behavioral therapy as first-line, real-world prescribing patterns continue to favor hypnotic medication. Family physicians prescribe sedative-hypnotics far more frequently than they refer for or deliver CBT-I, driven largely by access barriers, patient expectations, and time-pressured visits.
The pharmacologic landscape for chronic insomnia has also shifted considerably. Three dual orexin receptor antagonists have entered the market since 2014, while accumulating evidence has reinforced the harms of long-term benzodiazepine and Z-drug use. Family physicians need a framework that integrates first-line CBT-I, judicious pharmacotherapy, and structured deprescribing.
What Evidence Was Reviewed
This synthesis draws on contemporary clinical practice guidelines from the American Academy of Sleep Medicine and the American College of Physicians, the systematic reviews underpinning those guidelines, randomized phase 3 trials of dual orexin receptor antagonists, the largest randomized digital CBT-I trial, the EMPOWER cluster-randomized deprescribing trial, and observational data on hypnotic-related harms. Studies are anchored to randomized evidence first.
| Study (Year) | Design | Population | n | Intervention / Comparator | Key Outcomes |
|---|---|---|---|---|---|
| Edinger AASM CPG (2021) | Clinical practice guideline (GRADE) | Adults with chronic insomnia disorder | SR of 49 trials | Multicomponent CBT-I vs control | Strong recommendation for CBT-I as first-line |
| Qaseem ACP CPG (2016) | Clinical practice guideline (GRADE) | Adults with chronic insomnia disorder | SR of 35 RCTs (CBT-I); separate pharm review | CBT-I vs pharmacotherapy; pharm vs placebo | Strong recommendation: CBT-I as initial treatment |
| Sateia AASM Pharm CPG (2017) | Clinical practice guideline (GRADE) | Adults with chronic insomnia, CBT-I unavailable/declined | SR of pharmacologic agents | Multiple agents vs placebo | Weak (conditional) recommendations only |
| Trauer (2015) | Systematic review & meta-analysis | Adults with chronic insomnia | 20 RCTs, n = 1,162 | CBT-I vs control | SOL ↓ 19 min; SE ↑ 9.91 percentage points |
| Brasure ACP Evidence Report (2016) | Systematic review | Adults with chronic insomnia | 61 trials | Behavioral interventions vs control | CBT-I improves SOL, WASO, ISI; effects durable |
| Wilt ACP Evidence Report (2016) | Systematic review | Adults with chronic insomnia | 46 trials | Pharmacologic agents vs placebo | Modest short-term benefit; harms variable |
| Espie (2019) — dCBT-I | Pragmatic RCT | Adults with insomnia symptoms | 1,711 | Sleepio dCBT-I vs sleep hygiene education | Improved sleep, well-being, QoL at 24 weeks |
| Rosenberg / SUNRISE-1 (2019) | Phase 3 RCT | Adults ≥55 with insomnia disorder | 1,006 | Lemborexant 5/10 mg vs placebo and zolpidem ER 6.25 mg | Lemborexant superior to placebo and zolpidem ER |
| Mignot daridorexant (2022) | Two phase 3 RCTs | Adults with insomnia disorder | 1,854 | Daridorexant 25/50 mg vs placebo | WASO and LPS improved at 50 mg; somnolence higher |
| Kishi DORA NMA (2025) | Network meta-analysis, 8 RCTs | Adults with insomnia disorder | 5,198 | Suvorexant, lemborexant, daridorexant vs placebo | All DORAs superior to placebo on subjective sleep |
| Tannenbaum / EMPOWER (2014) | Cluster-randomized trial | Older adults on chronic benzodiazepines | 303 | Direct-to-patient education vs usual care | 27% vs 5% benzodiazepine discontinuation at 6 months |
| Tom (2016) | Case-control / cohort analysis | Older adults | 43,343 | Z-drug exposure vs non-exposure | Increased fall-related injury risk |
Key Findings From the Chronic Insomnia Evidence Base
Insight 1 — CBT-I Has the Strongest Evidence Base and Universal Guideline Endorsement
The AASM 2021 behavioral guideline assigns multicomponent CBT-I its single strong recommendation for chronic insomnia disorder in adults. The ACP 2016 guideline likewise issues a strong recommendation for CBT-I as initial treatment for all adults with chronic insomnia. World Sleep Society endorsement followed in 2023.
The supporting evidence is robust. The Trauer meta-analysis pooled 20 RCTs (n = 1,162) and demonstrated that CBT-I reduces sleep-onset latency by approximately 19 minutes and increases sleep efficiency by about 9.9 percentage points compared with control, with effects that persist months after treatment completion.
Insight 2 — Pharmacotherapy Recommendations Are Uniformly Weak
In striking contrast to the strong CBT-I recommendation, the AASM 2017 pharmacologic guideline issues only weak (conditional) recommendations across every drug class for chronic insomnia. The recommendations are agent- and pattern-specific: certain drugs are conditionally recommended for sleep-onset insomnia, others for sleep-maintenance insomnia, and most are recommended against for routine use.
The ACP echoes this hierarchy. Their guideline frames pharmacotherapy as a short-term option for adults with chronic insomnia in whom CBT-I alone is unsuccessful, and explicitly cautions against indefinite hypnotic use. Patient preferences and CBT-I access constraints are recognized as legitimate reasons to consider initial pharmacotherapy.
Insight 3 — Dual Orexin Receptor Antagonists Address Several GABA-Related Drawbacks
Three dual orexin receptor antagonists are FDA-approved for insomnia: suvorexant (2014), lemborexant (2019), and daridorexant (2022). A 2025 network meta-analysis of 8 randomized trials (n = 5,198) found all three superior to placebo for subjective sleep-onset latency, total sleep time, and Insomnia Severity Index scores at one month.
Mechanistically, dual orexin receptor antagonists block wake-promoting orexin signaling rather than enhancing GABA-mediated sedation. Practical advantages include the absence of physiologic tolerance, withdrawal, or rebound insomnia on abrupt discontinuation in available trial data, and unchanged sleep architecture. The principal trade-off is increased next-day somnolence relative to placebo.
In the SUNRISE-1 trial, lemborexant 5 mg and 10 mg outperformed both placebo and zolpidem extended-release 6.25 mg in adults aged 55 and older with chronic insomnia, on objective sleep measures over one month. This direct comparison is notable because it tested a dual orexin receptor antagonist against the most commonly prescribed Z-drug in older adults.
Insight 4 — Benzodiazepines and Z-Drugs Carry Meaningful Risks, Particularly in Older Adults
Benzodiazepines and Z-drugs (zolpidem, zaleplon, eszopiclone) provide modest short-term improvement in sleep but are associated with falls, fractures, motor vehicle collisions, complex sleep behaviors, dependence, and rebound insomnia on discontinuation. Observational analyses link Z-drug exposure to increased fall-related injury in older adults.
The 2023 AGS Beers Criteria continue to recommend against routine benzodiazepine use in adults aged 65 and older for insomnia, and they list Z-drugs as potentially inappropriate medications when used for more than 90 days. These signals reinforce that long-term use of GABA-modulating hypnotics is rarely supported by the evidence base.
Insight 5 — Digital CBT-I Resolves the Access Bottleneck
The chief barrier to first-line therapy for chronic insomnia in primary care has historically been access to trained CBT-I clinicians. Digital CBT-I platforms — including Sleepio, SHUTi, and the FDA-cleared Somryst — deliver structured CBT-I content asynchronously, with multiple meta-analyses confirming efficacy comparable to in-person therapy on most outcomes.
In the Espie 2019 randomized trial of 1,711 adults, digital CBT-I produced significant improvements in sleep, psychological well-being, and sleep-related quality of life at 24 weeks compared with sleep hygiene education alone. This evidence base supports digital CBT-I as a practical entry point for chronic insomnia management when in-person therapy is unavailable.
Clinical Pearl. The clinical question for the patient with chronic insomnia is no longer whether to use CBT-I — guidelines uniformly endorse it — but how to deliver it. In family medicine, the practical sequence is: brief behavioral counseling at the visit, followed by a digital CBT-I referral, with pharmacotherapy reserved for those who cannot or will not engage with behavioral therapy.
Quality and Consistency of the Evidence
The chronic insomnia evidence base is unusual among common primary care conditions in that the strongest evidence supports a non-pharmacologic intervention. Major guidelines built on systematic reviews using GRADE methodology converge on this conclusion. Pharmacologic data are more heterogeneous and graded lower across nearly every agent.
What the Evidence Does Not Show
Specific Gaps in the Chronic Insomnia Evidence Base
- No head-to-head randomized trials directly compare the three available dual orexin receptor antagonists on objective sleep, daytime function, or long-term safety endpoints.
- Long-term comparative effectiveness of CBT-I versus dual orexin receptor antagonists beyond 6–12 months is not established by randomized data.
- Optimal CBT-I delivery format (in-person, group, digital, hybrid) for different insomnia phenotypes has not been definitively determined.
- Evidence in patients with chronic insomnia and comorbid serious mental illness, advanced cognitive impairment, or significant frailty remains limited; most trials excluded these populations.
- The ideal tapering schedule and adjunctive supports for benzodiazepine and Z-drug deprescribing in long-term users have not been established by adequately powered randomized trials.
- Cost-effectiveness data comparing pharmacologic and non-pharmacologic strategies, particularly accounting for digital CBT-I, are incomplete.
Closing these evidence gaps will require pragmatic randomized trials embedded in primary care, head-to-head comparisons of the three FDA-approved dual orexin receptor antagonists, and structured deprescribing trials integrating CBT-I with hypnotic taper.
Practical Implications for Chronic Insomnia in Family Medicine
Based on the current evidence, the family physician’s task in chronic insomnia is to translate guideline endorsement of CBT-I into actionable practice while reserving pharmacotherapy for clearly defined indications. The four cards below describe what evidence supports rather than directive prescribing rules.
Evidence Supports CBT-I as Default First-Line Therapy
Multicomponent CBT-I delivered over 4 to 8 sessions has the strongest randomized evidence base for this condition and is endorsed strongly by both AASM and ACP. Components include sleep restriction, stimulus control, cognitive therapy, and sleep education.
Digital CBT-I Provides a Practical Access Pathway
When trained CBT-I clinicians are unavailable, digital CBT-I platforms have randomized evidence supporting clinically meaningful improvement. This is often the most realistic first-line option in primary care.
Dual Orexin Antagonists Offer a Safer Pharmacologic Pathway
When pharmacotherapy is needed, dual orexin receptor antagonists show consistent superiority over placebo without GABA-related adverse effects. They are reasonable alternatives to benzodiazepine receptor agonists, particularly in older adults.
Deprescribing Long-Term Benzodiazepines Is Evidence-Supported
Direct patient education combined with structured taper achieves meaningful discontinuation rates. The EMPOWER trial demonstrated 27% benzodiazepine discontinuation at 6 months, supporting active rather than passive review of long-term hypnotic prescriptions.
The evidence supports a sequenced approach. Start with a focused assessment to confirm chronic insomnia disorder per ICSD-3 criteria (difficulty initiating or maintaining sleep, with daytime consequences, occurring at least three nights per week for at least three months) and screen for contributors such as obstructive sleep apnea, restless legs, mood disorders, and substance use.
- Step 1. Provide brief in-visit behavioral counseling: stimulus control instructions, fixed wake time, and time-in-bed restriction principles.
- Step 2. Refer to digital CBT-I (Sleepio, SHUTi, or Somryst) or to a trained CBT-I clinician where available; reassess in 6 to 8 weeks.
- Step 3. If pharmacotherapy is required, match the agent to the insomnia pattern and the patient’s age and comorbidities; prefer dual orexin receptor antagonists over benzodiazepines or Z-drugs in adults 65 and older.
- Step 4. Set an explicit re-evaluation date for any hypnotic prescription, and pair pharmacotherapy with a CBT-I plan whenever feasible.
The three FDA-approved dual orexin receptor antagonists differ in pharmacokinetics rather than mechanism. Suvorexant (10–20 mg) was the first approved and has the longest half-life. Lemborexant (5–10 mg) was tested directly against zolpidem extended-release in older adults with chronic insomnia and showed superiority. Daridorexant (25–50 mg) has the shortest half-life of the three, which may favor patients particularly vulnerable to next-day sedation.
No head-to-head trials directly compare the three agents. Choice in family medicine is therefore typically driven by formulary access, comorbidity profile, and the predominant insomnia pattern (sleep-onset versus sleep-maintenance).
The EMPOWER cluster-randomized trial demonstrated that direct-to-patient educational materials describing benzodiazepine harms produced a 27% discontinuation rate at 6 months in older adults, compared with 5% in usual care. This effect was driven by patient-initiated conversations with their physicians.
A practical deprescribing approach for long-term benzodiazepine users with chronic insomnia includes three components:
- Direct patient education about benzodiazepine-related risks, ideally written.
- A gradual dose-tapering schedule (typically 25% reduction every 2 weeks).
- Concurrent CBT-I or digital CBT-I to address underlying chronic insomnia and prevent rebound symptoms.
Evidence Grade and Bottom Line
Evidence Grade — Strong (CBT-I as first-line for chronic insomnia); Moderate (dual orexin receptor antagonists when pharmacotherapy required); Limited (long-term comparative effectiveness and head-to-head DORA data). The evidence supporting CBT-I as first-line treatment for chronic insomnia is unusual in primary care for both its strength and its consistency across guideline-issuing bodies.
Bottom Line
- CBT-I is the first-line treatment for chronic insomnia disorder in adults, supported by strong recommendations from both the AASM and ACP based on consistent randomized evidence with durable effects.
- Digital CBT-I extends access to evidence-based therapy in primary care settings where trained clinicians are unavailable, with randomized evidence supporting clinically meaningful improvements.
- Dual orexin receptor antagonists are reasonable pharmacologic alternatives when behavioral therapy is unavailable or unsuccessful for chronic insomnia, with a more favorable safety profile than benzodiazepines or Z-drugs.
- Long-term benzodiazepine and Z-drug use for chronic insomnia is rarely supported by the evidence base; structured deprescribing achieves meaningful discontinuation rates and is supported by randomized data in older adults.
- Important uncertainties remain about long-term comparative effectiveness, head-to-head dual orexin receptor antagonist data, and outcomes in frail older adults — current decisions should be framed as time-limited and reviewable.
Article Information and References
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255–262. DOI: 10.5664/jcsm.8986
- Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(2):263–298. DOI: 10.5664/jcsm.8988
- Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD; Clinical Guidelines Committee of the American College of Physicians. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;165(2):125–133. DOI: 10.7326/M15-2175
- Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(2):307–349. DOI: 10.5664/jcsm.6470
- Trauer JM, Qian MY, Doyle JS, Rajaratnam SMW, Cunnington D. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(3):191–204. DOI: 10.7326/M14-2841
- Brasure M, Fuchs E, MacDonald R, et al. Psychological and Behavioral Interventions for Managing Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. 2016;165(2):113–124. DOI: 10.7326/M15-1782
- Wilt TJ, MacDonald R, Brasure M, et al. Pharmacologic Treatment of Insomnia Disorder: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. 2016;165(2):103–112. DOI: 10.7326/M15-1781
- Espie CA, Emsley R, Kyle SD, et al. Effect of Digital Cognitive Behavioral Therapy for Insomnia on Health, Psychological Well-being, and Sleep-Related Quality of Life: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(1):21–30. DOI: 10.1001/jamapsychiatry.2018.2745
- Rosenberg R, Murphy P, Zammit G, et al. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial. JAMA Netw Open. 2019;2(12):e1918254. DOI: 10.1001/jamanetworkopen.2019.18254
- Mignot E, Mayleben D, Fietze I, et al. Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurol. 2022;21(2):125–139. DOI: 10.1016/S1474-4422(21)00436-1
- Kishi T, Ikuta T, Citrome L, et al. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Transl Psychiatry. 2025;15:211. DOI: 10.1038/s41398-025-03439-8
- Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–898. DOI: 10.1001/jamainternmed.2014.949
- Tom SE, Wickwire EM, Park Y, Albrecht JS. Nonbenzodiazepine sedative hypnotics and risk of fall-related injury. Sleep. 2016;39(5):1009–1014. DOI: 10.5665/sleep.5742
- By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081. DOI: 10.1111/jgs.18372